Bruce Power to supply medical isotope supplies to European medical company

Graphic supplied by Bruce Power. 2019

Bruce Power has agreed to use their reactors to supply a European medical company.

ITM Medical Isotopes GmbH, a German company, and Isogen have agreed to supply Lutetium-177 to the world’s health-care system using Bruce Power reactors as a key supply source. ITM Medical Isotopes GmbH, based in Munich, is a subsidiary of the biotechnology and radiopharmaceutical group of companies Isotopen Technologien München AG. Isogen is a joint venture between nuclear companies Framatome and Kinectrics.

The new agreement will help supply medical-grade isotopes to the global medical community to treat numerous conditions and illnesses, including cancer, as well as sterilization of medical equipment. Production of Lutetium-177 at Bruce Power is expected to start in 2022.

Vic Fedeli, Minister of Economic Development, Job Creation and Trade, praised the partnership.

“Ontario continues to position itself as a world leader in the production of life-saving medical isotopes,” said Minister Fedeli. “The innovation of Ontario companies and international partnerships are critical to ensuring Ontario’s economic recovery from the COVID-19 outbreak. Today’s announcement is further proof that Ontario is open for business, open for jobs and open for investment.”

“This is an exciting day as we move into the next phase of our isotope program,” said Mike Rencheck, Bruce Power’s president and CEO. “Bruce Power is proud of its role as supplier of critical medical isotopes, including 40 per cent of the world’s Cobalt-60, which has been essential in the fight against COVID-19.”

Rencheck added, “as we look towards the future, the Isotope Production System is a game-changer that will allow us to access a key neutron source in our reactors, and create unprecedented capacity and redundancy of isotope production to improve global access to these innovative tools in the fight against cancer. Today’s announcement is a big step forward in achieving our goal of long-term, sustainable, and flexible production of medical isotopes at the Bruce Power site.”